Merck files for FDA approval of Keytruda in lung cancer

April 19, 2015 12:02 PM

14 0

(Reuters) - Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease.

Keytruda, also known as pembrolizumab, is currently approved by the FDA for patients with advanced melanoma who are no longer responding to other therapies.

Read more

To category page